Compare SCL & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCL | TNDM |
|---|---|---|
| Founded | 1932 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1994 | 2013 |
| Metric | SCL | TNDM |
|---|---|---|
| Price | $61.73 | $16.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 25 |
| Target Price | N/A | ★ $27.76 |
| AVG Volume (30 Days) | 128.9K | ★ 2.0M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,803,737,000.00 | $1,014,736,000.00 |
| Revenue This Year | $8.56 | $5.69 |
| Revenue Next Year | $5.92 | $12.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $41.82 | $12.26 |
| 52 Week High | $68.00 | $29.65 |
| Indicator | SCL | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 45.60 |
| Support Level | $60.06 | $14.66 |
| Resistance Level | $64.89 | $18.13 |
| Average True Range (ATR) | 1.56 | 0.84 |
| MACD | -0.07 | 0.18 |
| Stochastic Oscillator | 48.06 | 66.12 |
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.